Details of the Drug

General Information of Drug (ID: DM70DTN)

Drug Name
Flibanserin
Synonyms
Flibanserin [USAN]; Bimt 17; Bimt-17; 1,3-Dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-2H-benzimidazol-2-one; 1-(2-(4-(3-Trifluoromethylphenyl)piperazin-1-yl)ethyl)benzimidazol(1H)-2-one; 1-(2-(4-(alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone; 1-(2-(4-alpha,alpha,alpha-Trifluoro-m-tolyl)-1-piperazinyl)ethyl)-2-benzimidazolinone; 3-[2-[4-[4-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one
Indication
Disease Entry ICD 11 Status REF
Depression 6A70-6A7Z Approved [1]
Hypoactive sexual desire disorder N.A. Approved [1]
Mood disorder 6A60-6E23 Approved [2]
Psychosexual disorder N.A. Approved [1]
Female sexual arousal dysfunction HA01.1 Phase 3 [2]
Affected Organisms
Humans and other mammals
ATC Code
G02CX02: Flibanserin
G02CX: Other gynecologicals
G02C: OTHER GYNECOLOGICALS
G02: OTHER GYNECOLOGICALS
G: GENITO URINARY SYSTEM AND SEX HORMONES
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 390.4
Logarithm of the Partition Coefficient (xlogp) 3.3
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Bioavailability
The bioavailability of drug is 33% []
Half-life
The concentration or amount of drug in body reduced by one-half in 11 hours [4]
Metabolism
The drug is metabolized via the CYP3A4 []
Chemical Identifiers
Formula
C20H21F3N4O
IUPAC Name
3-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one
Canonical SMILES
C1CN(CCN1CCN2C3=CC=CC=C3NC2=O)C4=CC=CC(=C4)C(F)(F)F
InChI
InChI=1S/C20H21F3N4O/c21-20(22,23)15-4-3-5-16(14-15)26-11-8-25(9-12-26)10-13-27-18-7-2-1-6-17(18)24-19(27)28/h1-7,14H,8-13H2,(H,24,28)
InChIKey
PPRRDFIXUUSXRA-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
6918248
ChEBI ID
CHEBI:90865
CAS Number
167933-07-5
UNII
37JK4STR6Z
DrugBank ID
DB04908
TTD ID
D0S9CB
INTEDE ID
DR0701
ACDINA ID
D00279
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
5-HT 1A receptor (HTR1A) TTSQIFT 5HT1A_HUMAN Modulator [5]
5-HT 2A receptor (HTR2A) TTJQOD7 5HT2A_HUMAN Modulator [5]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [6]
Mephenytoin 4-hydroxylase (CYP2C19) DEGTFWK CP2CJ_HUMAN Substrate [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Depression
ICD Disease Classification 6A70-6A7Z
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
5-HT 1A receptor (HTR1A) DTT HTR1A 2.18E-01 -0.11 -0.51
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 6.32E-02 1.30E-01 7.89E-01
Mephenytoin 4-hydroxylase (CYP2C19) DME CYP2C19 5.49E-01 5.15E-02 1.92E-01
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 3.18E-03 2.30E-01 2.71E+00
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 8.32E-01 4.74E-02 1.73E-01
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Flibanserin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Metreleptin DM1NOEK Moderate Increased metabolism of Flibanserin caused by Metreleptin mediated induction of CYP450 enzyme. Acute diabete complication [5A2Y] [8]
Ivosidenib DM8S6T7 Moderate Increased metabolism of Flibanserin caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [8]
Arn-509 DMT81LZ Major Increased metabolism of Flibanserin caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [8]
Oliceridine DM6MDCF Moderate Additive CNS depression effects by the combination of Flibanserin and Oliceridine. Acute pain [MG31] [8]
Mepyramine DMB4SFH Moderate Additive CNS depression effects by the combination of Flibanserin and Mepyramine. Allergic/hypersensitivity disorder [4A80-4A8Z] [9]
Phenyltoloxamine DMKAEQW Moderate Additive CNS depression effects by the combination of Flibanserin and Phenyltoloxamine. Allergic/hypersensitivity disorder [4A80-4A8Z] [9]
Troleandomycin DMUZNIG Major Decreased metabolism of Flibanserin caused by Troleandomycin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [8]
Retigabine DMGNYIH Moderate Additive CNS depression effects by the combination of Flibanserin and Retigabine. Behcet disease [4A62] [8]
Cariprazine DMJYDVK Moderate Additive CNS depression effects by the combination of Flibanserin and Cariprazine. Bipolar disorder [6A60] [8]
Talazoparib DM1KS78 Moderate Decreased clearance of Flibanserin due to the transporter inhibition by Talazoparib. Breast cancer [2C60-2C6Y] [10]
Tucatinib DMBESUA Major Decreased metabolism of Flibanserin caused by Tucatinib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [8]
Palbociclib DMD7L94 Moderate Decreased metabolism of Flibanserin caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [8]
Bosutinib DMTI8YE Moderate Decreased clearance of Flibanserin due to the transporter inhibition by Bosutinib. Breast cancer [2C60-2C6Y] [11]
Indacaterol DMQJHR7 Minor Decreased clearance of Flibanserin due to the transporter inhibition by Indacaterol. Chronic obstructive pulmonary disease [CA22] [12]
Levomilnacipran DMV26S8 Moderate Additive CNS depression effects by the combination of Flibanserin and Levomilnacipran. Chronic pain [MG30] [8]
Fidaxomicin DMFP6MV Minor Decreased clearance of Flibanserin due to the transporter inhibition by Fidaxomicin. Clostridium difficile enterocolitis [1A04] [13]
Intedanib DMSTA36 Moderate Decreased metabolism of Flibanserin caused by Intedanib mediated inhibition of CYP450 enzyme. Colorectal cancer [2B91] [14]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Flibanserin caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [8]
Lumacaftor DMCLWDJ Major Increased metabolism of Flibanserin caused by Lumacaftor mediated induction of CYP450 enzyme. Cystic fibrosis [CA25] [15]
MK-8228 DMOB58Q Major Decreased metabolism of Flibanserin caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [8]
Rivaroxaban DMQMBZ1 Moderate Decreased metabolism of Flibanserin caused by Rivaroxaban mediated inhibition of CYP450 enzyme. Deep vein thrombosis [BD71] [16]
Vilazodone DM4LECQ Moderate Decreased metabolism of Flibanserin caused by Vilazodone mediated inhibition of CYP450 enzyme. Depression [6A70-6A7Z] [8]
Vortioxetine DM6F1PU Moderate Additive CNS depression effects by the combination of Flibanserin and Vortioxetine. Depression [6A70-6A7Z] [8]
Desvenlafaxine DMHD4PE Moderate Additive CNS depression effects by the combination of Flibanserin and Desvenlafaxine. Depression [6A70-6A7Z] [8]
OPC-34712 DMHG57U Moderate Additive CNS depression effects by the combination of Flibanserin and OPC-34712. Depression [6A70-6A7Z] [8]
Deutetrabenazine DMUPFLI Moderate Additive CNS depression effects by the combination of Flibanserin and Deutetrabenazine. Dystonic disorder [8A02] [8]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Flibanserin and Ingrezza. Dystonic disorder [8A02] [8]
Methsuximide DM6L5VO Moderate Additive CNS depression effects by the combination of Flibanserin and Methsuximide. Epilepsy/seizure [8A61-8A6Z] [8]
Cenobamate DM8KLU9 Moderate Decreased metabolism of Flibanserin caused by Cenobamate mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [8]
Stiripentol DMMSDOY Major Decreased metabolism of Flibanserin caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [8]
Brivaracetam DMSEPK8 Moderate Additive CNS depression effects by the combination of Flibanserin and Brivaracetam. Epilepsy/seizure [8A61-8A6Z] [8]
Lacosamide DMVM6QR Moderate Additive CNS depression effects by the combination of Flibanserin and Lacosamide. Epilepsy/seizure [8A61-8A6Z] [8]
Rufinamide DMWE60C Moderate Additive CNS depression effects by the combination of Flibanserin and Rufinamide. Epilepsy/seizure [8A61-8A6Z] [8]
Cannabidiol DM0659E Moderate Additive CNS depression effects by the combination of Flibanserin and Cannabidiol. Epileptic encephalopathy [8A62] [8]
Tazemetostat DMWP1BH Moderate Increased metabolism of Flibanserin caused by Tazemetostat mediated induction of CYP450 enzyme. Follicular lymphoma [2A80] [8]
Dexlansoprazole DM1DBV5 Moderate Decreased metabolism of Flibanserin caused by Dexlansoprazole mediated inhibition of CYP450 enzyme. Gastro-oesophageal reflux disease [DA22] [8]
Ripretinib DM958QB Moderate Decreased clearance of Flibanserin due to the transporter inhibition by Ripretinib. Gastrointestinal stromal tumour [2B5B] [13]
Boceprevir DMBSHMF Major Decreased metabolism of Flibanserin caused by Boceprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [8]
Telaprevir DMMRV29 Major Decreased metabolism of Flibanserin caused by Telaprevir mediated inhibition of CYP450 enzyme. Hepatitis virus infection [1E50-1E51] [8]
Brentuximab vedotin DMWLC57 Moderate Decreased clearance of Flibanserin due to the transporter inhibition by Brentuximab vedotin. Hodgkin lymphoma [2B30] [17]
Cobicistat DM6L4H2 Major Decreased metabolism of Flibanserin caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [8]
BMS-201038 DMQTAGO Moderate Decreased metabolism of Flibanserin caused by BMS-201038 mediated inhibition of CYP450 enzyme. Hyper-lipoproteinaemia [5C80] [8]
Aliskiren DM1BV7W Moderate Decreased metabolism of Flibanserin caused by Aliskiren mediated inhibition of CYP450 enzyme. Hypertension [BA00-BA04] [18]
Tolvaptan DMIWFRL Moderate Decreased clearance of Flibanserin due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [19]
Belladonna DM2RBWK Moderate Additive CNS depression effects by the combination of Flibanserin and Belladonna. Infectious gastroenteritis/colitis [1A40] [8]
Berotralstat DMWA2DZ Major Decreased metabolism of Flibanserin caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [8]
Suvorexant DM0E6S3 Moderate Additive CNS depression effects by the combination of Flibanserin and Suvorexant. Insomnia [7A00-7A0Z] [8]
Tasimelteon DMLOQ1V Moderate Additive CNS depression effects by the combination of Flibanserin and Tasimelteon. Insomnia [7A00-7A0Z] [8]
Paraldehyde DMOC1BX Moderate Additive CNS depression effects by the combination of Flibanserin and Paraldehyde. Insomnia [7A00-7A0Z] [8]
ITI-007 DMUQ1DO Moderate Additive CNS depression effects by the combination of Flibanserin and ITI-007. Insomnia [7A00-7A0Z] [8]
Naloxegol DML0B41 Minor Decreased metabolism of Flibanserin caused by Naloxegol mediated inhibition of CYP450 enzyme. Large intestine motility disorder [DB32] [20]
Crizotinib DM4F29C Major Decreased metabolism of Flibanserin caused by Crizotinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [8]
Ceritinib DMB920Z Major Decreased metabolism of Flibanserin caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [8]
Lurbinectedin DMEFRTZ Moderate Decreased metabolism of Flibanserin caused by Lurbinectedin mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [21]
PF-06463922 DMKM7EW Moderate Increased metabolism of Flibanserin caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [8]
Pralsetinib DMWU0I2 Moderate Decreased metabolism of Flibanserin caused by Pralsetinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [22]
Selpercatinib DMZR15V Moderate Decreased metabolism of Flibanserin caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [8]
Idelalisib DM602WT Major Decreased metabolism of Flibanserin caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [8]
GDC-0199 DMH0QKA Major Decreased clearance of Flibanserin due to the transporter inhibition by GDC-0199. Mature B-cell leukaemia [2A82] [13]
IPI-145 DMWA24P Major Decreased metabolism of Flibanserin caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [8]
Vemurafenib DM62UG5 Moderate Increased metabolism of Flibanserin caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [8]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Flibanserin caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [11]
Allopregnanolone DMNLHAC Moderate Additive CNS depression effects by the combination of Flibanserin and Allopregnanolone. Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z] [23]
Lasmiditan DMXLVDT Moderate Additive CNS depression effects by the combination of Flibanserin and Lasmiditan. Migraine [8A80] [24]
Romidepsin DMT5GNL Moderate Decreased clearance of Flibanserin due to the transporter inhibition by Romidepsin. Mycosis fungoides [2B01] [25]
Fedratinib DM4ZBK6 Major Decreased metabolism of Flibanserin caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [8]
Rolapitant DM8XP26 Moderate Decreased clearance of Flibanserin due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [26]
Netupitant DMEKAYI Major Decreased metabolism of Flibanserin caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [8]
E-2007 DMJDYNQ Moderate Additive CNS depression effects by the combination of Flibanserin and E-2007. Neuropathy [8C0Z] [8]
Entrectinib DMMPTLH Moderate Decreased metabolism of Flibanserin caused by Entrectinib mediated inhibition of CYP450 enzyme. Non-small cell lung cancer [2C25] [8]
S-297995 DM26IH8 Moderate Decreased metabolism of Flibanserin caused by S-297995 mediated inhibition of CYP450 enzyme. Opioid use disorder [6C43] [11]
Rucaparib DM9PVX8 Moderate Decreased metabolism of Flibanserin caused by Rucaparib mediated inhibition of CYP450 enzyme. Ovarian cancer [2C73] [8]
Opicapone DM1BKA6 Moderate Additive CNS depression effects by the combination of Flibanserin and Opicapone. Parkinsonism [8A00] [8]
Abametapir DM2RX0I Moderate Decreased metabolism of Flibanserin caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [27]
Lefamulin DME6G97 Moderate Decreased metabolism of Flibanserin caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [28]
Lonafarnib DMGM2Z6 Major Decreased metabolism of Flibanserin caused by Lonafarnib mediated inhibition of CYP450 enzyme. Premature ageing appearance [LD2B] [8]
Enzalutamide DMGL19D Major Increased metabolism of Flibanserin caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [8]
Relugolix DMK7IWL Major Decreased clearance of Flibanserin due to the transporter inhibition by Relugolix. Prostate cancer [2C82] [29]
Neupro DMHEAB1 Moderate Additive CNS depression effects by the combination of Flibanserin and Neupro. Restless legs syndrome [7A80] [8]
Iloperidone DM6AUFY Moderate Additive CNS depression effects by the combination of Flibanserin and Iloperidone. Schizophrenia [6A20] [8]
Asenapine DMSQZE2 Moderate Additive CNS depression effects by the combination of Flibanserin and Asenapine. Schizophrenia [6A20] [8]
Voxelotor DMCS6M5 Major Decreased metabolism of Flibanserin caused by Voxelotor mediated inhibition of CYP450 enzyme. Sickle-cell disorder [3A51] [8]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Flibanserin caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [11]
Larotrectinib DM26CQR Moderate Decreased metabolism of Flibanserin caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [8]
Armodafinil DMGB035 Moderate Increased metabolism of Flibanserin caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [8]
LEE011 DMMX75K Major Decreased metabolism of Flibanserin caused by LEE011 mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [8]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Flibanserin caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [30]
Apixaban DM89JLN Moderate Decreased clearance of Flibanserin due to the transporter inhibition by Apixaban. Thrombosis [DB61-GB90] [11]
Brilinta DMBR01X Moderate Decreased metabolism of Flibanserin caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [8]
Elagolix DMB2C0E Moderate Increased metabolism of Flibanserin caused by Elagolix mediated induction of CYP450 enzyme. Uterine fibroid [2E86] [8]
Acrivastine DMTIGA0 Moderate Additive CNS depression effects by the combination of Flibanserin and Acrivastine. Vasomotor/allergic rhinitis [CA08] [8]
⏷ Show the Full List of 91 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Carmellose sodium E00625 Not Available Disintegrant
Eisenoxyd E00585 56841934 Colorant
Lactose monohydrate E00393 104938 Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate E00208 11177 lubricant
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
⏷ Show the Full List of 6 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Flibanserin 100 mg tablet 100 mg Oral Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Flibanserin FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8182).
3 BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
6 Flibanserin: first global approval. Drugs. 2015 Oct;75(15):1815-22.
7 Flibanserin therapy and CYP2C19 genotype.
8 Product Information. Addyi (flibanserin). Sprout Pharmaceuticals, Raleigh, NC.
9 Warrington SJ, Ankier SI, Turner P "Evaluation of possible interactions between ethanol and trazodone or amitriptyline." Neuropsychobiology 15 (1986): 31-7. [PMID: 3725002]
10 Product Information. Talzenna (talazoparib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
11 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
12 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
13 Cerner Multum, Inc. "Australian Product Information.".
14 Product Information. Ofev (nintedanib). Boehringer Ingelheim, Ridgefield, CT.
15 Patel S, Robinson R, Burk M "Hypertensive crisis associated with St. John's Wort." Am J Med 112 (2002): 507-8. [PMID: 11959071]
16 Product Information. Xarelto (rivaroxaban). Bayer Inc, Toronto, IA.
17 Product Information. Adcetris (brentuximab vedotin). Seattle Genetics Inc, Bothell, WA.
18 Canadian Pharmacists Association.
19 Product Information. Samsca (tolvaptan). Otsuka American Pharmaceuticals Inc, Rockville, MD.
20 Product Information. Movantik (naloxegol). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
21 Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
22 Product Information. Gavreto (pralsetinib). Blueprint Medicines Corporation, Cambridge, MA.
23 Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
24 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
25 Product Information. Istodax (romidepsin). Gloucester Pharmaceuticals, Cambridge, MA.
26 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
27 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
28 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
29 Product Information. Orgovyx (relugolix). Myovant Sciences, Inc., Brisbane, CA.
30 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.